Skip to content
ClinCalc Pro
Menu
Cardiology Respiratory Haematology Moderate — validated in prospective cohort studies

DASH Prediction Score for Recurrent VTE

Predicts the annual risk of recurrent VTE after discontinuing anticoagulation following a first unprovoked VTE event, to guide duration of therapy

Score interpretation

Low Recurrence Risk — ~3.1%/year -4–1

DASH ≤ 1: Low annual recurrence risk (~3.1%/year after stopping anticoagulation).

→ Stopping anticoagulation after 3–6 months may be appropriate for many patients. Discuss patient preferences, bleeding risk, and individual circumstances.

Intermediate Risk — ~6.4%/year 2

DASH = 2: Intermediate annual recurrence risk (~6.4%/year).

→ Individualise anticoagulation duration. Weigh recurrence risk vs bleeding risk. Consider extended therapy with patient involvement.

High Recurrence Risk — ~12.3%/year 3–6

DASH ≥ 3: High annual recurrence risk (~12.3%/year).

→ Extended indefinite anticoagulation likely warranted. DOAC preferred (apixaban 2.5mg bd or rivaroxaban 10mg od extended prophylaxis). Haematology/respiratory review.

Interpretation bands for the DASH Score. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

The DASH Score is covered in detail — with RCEM/NICE evidence base, indications and pitfalls — in the following exam-focused pathways on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.